peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Hansa Biopharma to host conference call to provide Year-end 2022 results and a Business Update

20 Jan 2023, 08:00

Lund, Sweden, January 20, 2023 Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its Year-end Report 2022 at 8:00 CET on February 2, 2023. All interested parties are invited to participate in a telephone conference, which will include a presentation of the year-end results and a business update, on the same date at 14:00 CET/8:00am EST. The event will be hosted by Hansa Biopharma’s CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.

Slides used in the presentation will be live on the company website during the call under “Events & Presentations” and will also be made available online after the call. Link to presentation

To participate in the telephone conference, please use the dial-in details provided below:

Sweden: +46 10 884 80 16

United Kingdom: +44 020 3936 2999

United States: +1 646 664 1960

Participant access code: 031372

The webcast will be available on

Financial calendar and events 2023

Feb 2, 2023         Interim Report for January-December 2022

Feb 9, 2023         Mid-cap event, Frankfurt

Feb 23, 2023       Erik Penser Healthcare Seminar, Stockholm

Mar 7, 2023         Redeye Healthcare Seminar: Commercialization, Stockholm

Mar 16, 2023       Carnegie Nordic Healthcare Seminar 2023, Stockholm

Mar 30, 2023       2022 Annual Report

April 4, 2023        Guggenheim Healthcare Talks Rare Disease Days

April 20, 2023      Interim Report for January-March 2023

April 20 2023       Redeye investor forum, Gothenburg

April 21 2023       Redeye lunch presentation, Stockholm

April 25 2023       Kempen Life Sciences Conference 2023, Amsterdam

May 11, 2023       Erik Penser Company Day, Malmö

May 11, 2023       Redeye investor forum, Malmö

May 25, 2023       Erik Penser Company Day, Stockholm

June 14, 2023      Annual General Meeting 2023

July 20, 2023       Half-year Report for January-June 2023

Oct 19, 2023        Interim Report for January-September 2023

For further information, please contact:

Klaus Sindahl, Head of Investor Relations
M: +46 (0) 709–298 269

Stephanie Kenney, VP Global Corporate Affairs
M: +1 (484) 319 2802

About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at